The Institute is the national reference center for infectious diseases.
The Institute is devoted to research and medical care in infectious disease with over 4000 patients cared yearly and, particularly it is a referral center for TB (at least 300 patients/yearly). The Institute is organized in four departments: clinical, diagnostic services and clinical research, epidemiology and pre-clinical research, transplants. The research is inspired by the integration of epidemiological, basic and applied (i.e. preclinical and clinical) research and its mission is to transfer knowledge gained from basic research to the clinic for improving the patient care quality.
Biomarkers\Epidemiology\Immunology\Infection\Tuberculosis – TB
Global fellowships (return phase only)\ European fellowships
The Institute is devoted to research and medical care of infectious diseases. To this aim, it is organized with several core facilities such as Biocontainment Laboratories, Biorepository, Massively Parallel Pyrosequencing, Sanger Sequencing, Proteomic, Flow Cytometry, Ultrastructural imaging, BSL3 autopsy laboratory and Drug Monitoring.
Over 4,000 patients are cared yearly including more than 300 patients with active TB and 600 with LTBI. In particular Translational Research laboratory has a large experience on TB immunology and on the study of new biomarkers of Mtb infection. Lab expertise includes flow cytometry, molecular biology, cell expression, cell biology.
The Institute has several lines of funding:
1. Italian Ministry of Health “Ricerca Corrente”
2. Italian Ministry of Health “Ricerca Finalizzata” Characterization of the immune response to M.tuberculosis in patients with latent tuberculosis infection at higher risk to develop active TB disease because candidate to biological treatment “GR-2018-12367178”; New players in tuberculosis vaccine development: mycobacterial small regulatory RNAs for attenuating virulence of Mycobacterium tuberculosis (GR-2013-02357850)
3. The Horizon2020 research project TBVAC2020 aimed to innovate and diversify the current TB vaccine (and biomarker) pipeline for TB diagnosis
The Institute collaborates with companies for different fields of application. In particular for the respiratory field.
– ReiThera S.r.l. to develop vaccines based on a new adenoviral vector (GRAd23)
– Quidel to develop new assays for TB diagnosis
– PBD Biotech to develop new assays for TB diagnosis
– BioMérieux to develop new assays for TB diagnosis
INMI offers multiple opportunities to foreign scientists to help with the difficulties they may face when moving to Rome and working at INMI. For the academic career development, our department offers the possibility to be trained at the Internal training program for employees (e.g. communication skills with patients, microbiology, virology, immunological, proteomic, electron microscopy, translationa research and infectious diseases courses) . INMI hosts international researchers under schemes such as Marie Sklodowska-Curie Fellowships, ERS Fellowships and visiting researchers.
INMI wants to inspire curiosity about science and infectious diseases in particular, connecting with the civil society and generating discussion between researchers and the public.